FOSUN PHARMA - Announcement of Resolutions of the 32nd Meeting of the 10th Board of Directors (Extraordinary Meeting)
FOSUN PHARMA - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
make any statement and expressly disclaim any liability for any damages whatsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
assumes no responsibility for any failure.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (a joint stock limited company incorporated in the People's Republic of China)
(Stock code: 02196)
Overseas regulatory announcement
This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
This is to set forth the "Tenth Annual Report" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (the "Company") on the website of the Shanghai Stock Exchange.
Announcement of Resolutions of the 32nd Meeting of the Board of Directors (Extraordinary Meeting)" is for reference only.
By order of the board of directors Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Chairman
Chen Yuqing
China, Shanghai
June 15, 2026
As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the Company The non-executive directors of the company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the company are Mr. Yu Zishan, Mr. Wang Quandi, and Mr. Chen Mr. Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.
*For identification only
Securities code: 600196 Stock abbreviation: Fosun Pharma Number: Lin 2026-081
Shanghai Shanghai Fufu Xingxing Medical and Pharmaceutical ((Group)) Co., Ltd.
Announcement of Resolutions of the 332nd Meeting of the 10th Session of the Board of Directors ((Interim Meeting))
The Board of Directors of the Company and all directors hereby certify that the contents of this announcement do not contain any false or misleading statements.
There may be any serious omissions or omissions, and we shall not be held legally responsible for the authenticity, accuracy and completeness of the content. .
The 10th Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the "Company")
The thirty-second meeting (extraordinary meeting) was held on June 15, 2026. All directors attended the meeting by communication.
The convening of this meeting complied with the Company Law of the People's Republic of China, other relevant laws and regulations and the Shanghai Fosun Articles of Association of Pharmaceutical (Group) Co., Ltd. The meeting reviewed and reached the following resolutions:
- Deliberation and approval of the increase in capital of Fuxing Antejin ((Chengdu)) Bio-Biopharmaceutical Co., Ltd., a controlling subsidiary of the company, was approved
Proposal to expand shares. .
Agree to hold subsidiary Fosun Entejin (Chengdu) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Fosun
Antjin") to Chengdu Guoshengceyuan Life Health Venture Capital Partners at a price of RMB 84.207235 per share Enterprise (Limited Partnership), China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership),
Shanghai Jingxurongxu Venture Capital Center (Limited Partnership)) and Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (named
(hereinafter referred to as "Fosun Pharmaceutical Industries") issued a total of 11,495,449 new shares (hereinafter referred to as "this capital increase").
"Expansion of shares"), among which: Fosun Pharmaceutical Industry invested RMB 550 million to subscribe for 6,531,505 shares.
At the same time, it is agreed to authorize the company's management or its authorized persons to handle specific matters related to this capital increase and share expansion. appropriate, including but not limited to signing, revising and executing relevant agreements.
Voting results: 12 votes in favor, 0 votes against, and 0 abstentions.
For details, please refer to the "Announcement on Capital Increase and Share Expansion of Controlled Subsidiaries" released on the same day.
- Deliberation and approval of the relevant matters regarding the controlling subsidiary company Fu Xing Ante Jinjin ((Chengdu)) Bio-Biopharmaceutical Co., Ltd. 22
Proposal for the second grant of the stock equity incentive plan. .
Agree that the controlled subsidiary Fosun Entejin will pay RMB 25.26/1 according to the second phase of the incentive plan that has been adopted. 111,000 restricted equity shares were granted to Mr. Chen Zhanyu (corresponding to Fosun Entejin
111,000 shares) (hereinafter referred to as "the grant").
At the same time, we agree to authorize the company's management or its authorized persons to handle specific matters related to this grant,
Including but not limited to signing, revising and executing relevant agreements.
Since Mr. Chen Zhanyu is a senior manager of the Company, according to the "Stock Listing Rules of the Shanghai Stock Exchange", It constitutes a related party of the company, and this grant constitutes a related transaction.
As Mr. Chen Zhanyu is a director of an important subsidiary of the Company, according to the "The Stock Exchange of Hong Kong Limited"
Securities Listing Rules", it constitutes a related party of the company, and this grant constitutes a connected transaction, but it is fully exempted
(Including) shareholder approval and announcements, etc.
Voting results: 12 votes in favor, 0 votes against, and 0 abstentions. This proposal has been approved in advance by a special meeting of independent non-executive directors before being submitted to the board of directors for review.
For details, please refer to the "Announcement on the Implementation Progress of Equity Incentives of Controlled Subsidiaries and Related Transactions" released on the same day.
Report".
Announcement is hereby made.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
board of directors
June 15, 2026